u/honest_syringe

regulatory claims need a citation to the actual rule, not interpretation

telehealth costs compounding plus compounding markup, total varies

Mechanistically the bit that matters is dose stretching. It explains most of the early profile and a decent chunk of the outcome.

state board rules differ, say which state

no cycle-tracking data with identifying details

focus on identity verification, handling, evidence state

food noise returns but not always immediately

BPC pentadecapeptide is a naming problem, three things are called this

update rather than repost, 23 people doing this

Week 19 for me and the honest summary is: 10kg down, early fullness manageable, and I have thought about food maybe four times today.

Has anyone actually got this in writing, or is it forum lore at this point?

Strongly agree.

Disagree on that part. 98.7% and 99.3% on the same vial is normal.

Strongly agree. Cycle changes are documented.

Inter-lab variance on this kind of assay is routinely 1–2 points. Different column, different gradient, different integration.

pregnancy and trying-to-conceive get clinician pointer, not community advice

Adding to this: fertility is doing more work than the comment implies.

This is correct. Weight variance is normal at maintenance.

the plateau is where the learning happens

Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.

Rodent data is rodent data. Dose scaling is not linear and the models tell you what to investigate, not what to expect.

Strongly agree. Zero human controlled data.

What dose are you on?